Academic Drug Discovery 2016 March 22-23 2016 Cam...

SELECTBIO is pleased to announce Academic Drug Discovery 2016, which will be held on 22 – 23 March 2016 in Cambridge, UK. The event is part of our Cambridge Workshop Series. Attracting a global audience of researchers, academics, group leaders, directors and the global heads of leading academic and open innovation drug discovery centres, this event will explore the current challenges and opportunities faced in academic...

11th EFMC Short Course on Medicinal Chemistry Engi...

This intensive course is intended for scientists with interests in the field of peptide and protein engineering covering topics around synthetic peptides, engineered proteins and therapeutic antibodies. The number of participants will be limited to 35 to assure the possibility for in-depth discussions. The presentations and tutorials will be given by academic and industrial experts and will cover broad historical perspectives...

Popular blood type diet debunked

Researchers from the University of Toronto (U of T) have found that the theory behind the popular blood type diet–which claims an individual’s nutritional needs vary by blood type–is not valid. The findings are published in PLoS One. “Based on the data of 1,455 study participants, we found no evidence to support the ‘blood-type’ diet theory,” said the senior author of the study, Dr....

Rare disease dictionary

While bioinformatics lies at the leading edge of biological research, it is still underpinned by one of the oldest tools available to humanity: communication. Recognizing this, researchers are trying to standardize terminology through the creation of a rare genetic disease dictionary. The project stemmed from rising awareness that while lots of researchers are working to identify rare diseases and their related genes, their...

StemCyte and UC Davis Tethered in Umbilical Cord B...

StemCyte entered an agreement with the UC Davis Umbilical Cord Blood Collection (UCB) Program to advance the collection, processing, and registration of high quality and diverse cord blood cells from California mothers for public banking. According to the company, the agreement is the first of its kind under California’s statewide program. Legislation signed into law in 2010 called for the University of California to...

Horizon Applies Gene Editing to Huntington’s Disea...

Horizon Discovery inked a gene-editing research collaboration with the Institute of Neurology, University College London. The partnership will focus on the creation of human isogenic disease model cell lines with insertion of Huntington’s disease-causing triplet repeats. The company will provide UCL with access to GENESIS, its rAAV-mediated human gene-editing platform. This collaboration is a novel one for Horizon:...